Menu
Recruiting NCT07093606

Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura

No phase Interventional ITP - Immune Thrombocytopenia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Eltrombopag.
Who it may be relevant to
Registry conditions: ITP - Immune Thrombocytopenia. Basic parameters: 18 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.

Interventions

  • Drug Eltrombopag
    ITP patients will receive Eltrombopag and evulate occurance of liver disordres .

Primary outcome measures

  • •To assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag. [Time frame: 3-6 months after receiving eltombopag]

Eligibility criteria

Inclusion Criteria Adult patients (≥18 years) diagnosed with primary ITP. Receiving eltrombopag as part of their treatment. Baseline liver function tests (LFTs) within normal limits. Patients with diabetes Patients without diabetes Patients with fatty liver Patients without fatty liver

Exclusion criteria

Pre-existing liver disease (e.g., hepatitis, cirrhosis, NAFLD). Concurrent use of hepatotoxic drugs. Patients lost to follow-up.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Other

Study locations

Egypt · 1 center
  • Sohag university hospital — Sohag

Publications

  • Bidika E, Fayyaz H, Salib M, Memon AN, Gowda AS, Rallabhandi B, Cancarevic I. Romiplostim and Eltrombopag in Immune Thrombocytopenia as a Second-Line Treatment. Cureus. 2020 Aug 21;12(8):e9920. doi: 10.7759/cureus.9920. PMID 32968581
  • Kuter DJ. New thrombopoietic growth factors. Blood. 2007 Jun 1;109(11):4607-16. doi: 10.1182/blood-2006-10-019315. Epub 2007 Feb 8. PMID 17289815
  • Ptushkin VV, Vinogradova OY, Pankrashkina MM, Chernikov MV, Arshanskaya EG, Tkachenko NE. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice. Ter Arkh. 2018 Aug 17;90(7):70-76. doi: 10.26442/terarkh201890770-76. PMID 30701925

Identifiers

NCT: NCT07093606 · Soh-Med--25-7-4MS

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗